EMA reports on marketing authorizations, as well as new initiatives in 2016

The European Medicines Agency’s 2016 annual report published today focuses on the Agency’s key achievements in the areas of medicine evaluation, support to research and development of new and innovative treatments and the safety monitoring of medicines in real life.

In 2016, the Agency recommended a marketing authorization for 81 medicines for human use, including 27 new active substances. This compares with 93 in 2015 and 82 in 2014, Many of these innovative substances build on the advances made in biomedical science and have the potential to make a difference for patients.

On the veterinary side, 11 medicines were recommended for approval, including six new active substances. A third of these medicines prevent viral or bacterial infections in food-producing animals.